This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prescribing Post-Exposure Prophylaxis Following Sexual Exposure (PEPSE)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

prescribing Post-Exposure Prophylaxis Following Sexual Exposure (PEPSE)

PEP is not considered 100% effective, as there have been cases of HIV acquisition whilst on PEP. These may be related to

  • delayed initiation
  • transmission of resistant virus
  • variable genital tract drug penetration
  • poor/non-adherence
  • further high risk sexual exposures

Recommendations of British Association of Sexual Health and HIV (BASHH):

  • PEPSE should be used where there is a significant risk of HIV transmission
  • HIV status of source is
    • unknown - proactive attempts are made to establish the HIV status
    • known to be positive
      • attempts should be made at the earliest opportunity to determine the HIV viral load, resistance profile and treatment history
      • PEPSE is no longer recommended if the source is on antiretroviral therapy (ART) with a confirmed and sustained (>6 months) undetectable plasma HIV viral load (<200c/ml)
        • however, if there are any doubts about the HIV viral load history or the source "s adherence to ART then PEP should be given following unprotected receptive anal intercourse
  • truvada and raltegravir is the regimen of choice for PEPSE
  • PEPSE should be initiated as soon as possible after exposure, preferably within 24 hours, but can be considered up to 72 hours
    • giving PEPSE beyond 72 hours is not recommended
  • duration of PEPSE should be 28 days
  • follow-up HIV testing at 8-12 weeks after exposure should be carried out
  • pregnancy testing should be undertaken in women considering PEPSE
    • pregnancy should not alter the decision to start PEPSE
    • women must be counselled that antiretroviral agents used for PEPSE are unlicensed in pregnancy and risks / benefits must be carefully discussed
  • in the event of a further high-risk sexual exposure in the last two days of the PEPSE course the PEP should be continued for 48 hours after the last high-risk exposure
  • if the HIV test is positive after PEPSE has already been initiated we recommend continuing PEPSE pending review by an HIV specialist
  • individuals experiencing a skin rash or flu-like illness during or after taking PEPSE should be advised to attend for urgent review to exclude an HIV seroconversion illness

Guidance on missed doses of PEPSE:

  • <24 hours elapsed since last dose - take missed doses immediately and subsequent doses at usual time
  • 24-48 hours elapsed since last dose - continue PEPSE
  • >48 hours since last dose - recommend to stop PEPSE (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.